NYSE
$285.01▼ 0.17%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $503.55BShares out 17.700M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 1d agoAfter-hours26.10.24 06:043Ownership
AbbVie Inc.
John Carethers, an executive at AbbVie Inc., has filed a Power of Attorney authorizing designated agents to prepare and submit SEC filings on his behalf. This authorization covers the filing of Forms 144, 3, 4, and 5 as required under the Securities Exchange Act.…more
$285.01-0.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15After-hours26.10.16 05:008-KKey event
AbbVie Inc.
AbbVie Inc. expanded its Board of Directors from twelve to thirteen members and appointed Dr. John M. Carethers as a new independent director, effective October 14, 2026. Dr. Carethers will serve on the Public Policy and Sustainability Committee and meets all independence standards.…more
$285.01-0.17%vs prev closeView filingShare - 10.5After-hours26.10.06 05:078-KKey event
AbbVie Inc.
AbbVie has updated its 2026 adjusted diluted EPS guidance to reflect $216 million in acquired IPR&D and milestone expenses incurred during the third quarter. Consequently, the full-year 2026 adjusted diluted EPS guidance range has been adjusted to $13.76 - $13.96, and the third-quarter 2026 adjusted diluted EPS guidance is set at $3.73 - $3.77.…more
$285.01-0.17%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.24 04:36Bullish#●●●#●●●
AbbVie Receives FDA Approval For SKYRIZI Crohn's Disease Treatment
AbbVie announced that the FDA has approved a subcutaneous induction regimen for SKYRIZI to treat moderately to severely active Crohn's disease. This approval allows patients to administer induction and maintenance doses at home using an on-body injector.…more
$285.01-0.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 2d agoRegular26.10.23 03:17
●●●●●●●● ●●●●● ●●●●●●
AbbVie's lutikizumab met its primary endpoint in a Phase 3 trial, but analysts noted that the efficacy results fell short of industry benchmarks. While the drug showed clinical benefits, concerns regarding its competitive positioning have tempered expectations for its market potential.…more
$285.01-0.17%vs prev closeShareBenzinga - 3d agoPre-market26.10.22 22:08
●●●●●●●● ●●●●● ●●●●●●
AbbVie reported that its phase 3 INTREPID study for lutikizumab met its primary and eight secondary endpoints in treating moderate to severe hidradenitis suppurativa. The drug demonstrated statistically significant clinical response and pain reduction, supporting its potential as a new treatment option.…more
$285.01-0.17%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report